Skip to main content
Immunohistochemistry (IHC) market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, UK, China - Size and Forecast 2024-2028

Immunohistochemistry (IHC) market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, UK, China - Size and Forecast 2024-2028

Published: Feb 2024 168 Pages SKU: IRTNTR76298

Market Overview at a Glance

$1.33 B
Market Opportunity
8.36%
CAGR
7.63
YoY growth 2023-2024(%)

Immunohistochemistry Market Size 2024-2028

The immunohistochemistry market size is forecast to increase by USD 1.33 billion at a CAGR of 8.36% between 2023 and 2028.

  • The Immunohistochemistry (IHC) market is experiencing significant growth due to the rising number of cancer patients worldwide. This increasing patient population necessitates advanced diagnostic techniques, driving the demand for IHC. Moreover, automation and technological advancements in IHC processes are enhancing diagnostic accuracy and efficiency. However, the high cost associated with IHC remains a challenge, limiting its accessibility in some regions. Despite this, the market is expected to continue its growth trajectory due to the increasing focus on personalized medicine and the need for precise and accurate diagnostic tools. IHC's ability to provide valuable insights into disease progression and treatment response makes it an essential tool In the healthcare industry.

    • What will be the Size of the Immunohistochemistry Market During the Forecast Period?

    Immunohistochemistry Market Size

     Request Free Sample

  • The Immunohistochemistry (IHC) market encompasses a range of products and services used In the detection and analysis of various proteins and biomarkers in cancer and other diseases through IHC tests. This market is driven by the increasing incidence of cancer diseases and the growing demand for accurate and reliable diagnostic testing. IHC tests play a crucial role in healthcare professionals' decision-making processes, guiding therapeutic interventions and companion diagnostics in cancer treatment. Advancements in digital pathology and IVD equipments have led to the emergence of digital IHC, enabling automated image analysis and increasing diagnostic accuracy. Key players in this market include Leica Biosystems and Akoya Biosciences, among others, who offer solutions for IHC, multiplex IHC, and immunofluorescence assay.
  • The market is also witnessing the development of monoclonal antibodies and antibody fragments for IHC, as well as the integration of immunotherapy trials and the therapeutic significance of immunology in infectious diseases. Laboratory consumables and diagnostic testing are essential components of the IHC market, with research organizations playing a pivotal role in advancing the technology. The standardization of IHC protocols and the automation of IHC processes are ongoing trends in this market. The use of IHC in diagnostic laboratories and the role of IHC In the development of antibody drugs further expand the market's scope.

    • How is this Immunohistochemistry Industry segmented and which is the largest segment?

    The immunohistochemistry industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

    • Application
      • Diagnostic application
      • Research application
      • Forensic application
    • End-user
      • Hospitals and diagnostic laboratories
      • Academic and research institutes
      • Others
    • Geography
      • North America
        • US
      • Europe
        • Germany
        • UK
        • France
      • Asia
        • China
      • Rest of World (ROW)

      By Application Insights

      • The diagnostic application segment is estimated to witness significant growth during the forecast period.

      Immunohistochemistry (IHC) is a vital diagnostic technique in pathology and molecular biology, enabling the identification and localization of specific proteins or antigens in tissue sections. This process utilizes antibodies that bind to the antigens, offering insights into disease mechanisms and biomarker discovery. IHC is particularly significant in oncology, where it assists in cancer diagnosis and therapy selection. With the growing understanding of various cancer types, including breast, colon, and lung cancer, the demand for IHC tests intensifies. Digital pathology and in vitro diagnostic (IVD) equipment facilitate automation and standardization, enhancing diagnostic accuracy. Key players In the market include Leica Biosystems, Akoya Biosciences, Roche, and others.

      Companion diagnostics and immunotherapy trials further emphasize the therapeutic significance of IHC. Chronic diseases, such as cardiovascular diseases (e.G., ischemic heart disease, stroke), and infectious diseases (e.G., monkeypox, viral epidemics) also benefit from IHC. Monoclonal antibodies, antibody fragments, and diagnostic kits are essential laboratory consumables. Healthcare professionals and research organizations leverage IHC for diagnostic testing and personalized medicine. Immunofluorescence assay is a related technique. Cancer incidence, antigen-antibody interactions, geriatric population, reimbursement policies, and chronic diseases influence market growth.

      Immunohistochemistry Market Size

      Get a glance at the  Immunohistochemistry Industry report of share of various segments Request Free Sample

      The Diagnostic application segment was valued at USD 1.30 billion in 2018 and showed a gradual increase during the forecast period.

      Regional Analysis

      • North America is estimated to contribute 38% to the growth of the global market during the forecast period.

      Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

      Immunohistochemistry Market Share by Geography

      For more insights on the market share of various regions, Request Free Sample

      Immunohistochemistry (IHC) plays a pivotal role in diagnosing and understanding various cancer diseases, chronic conditions, and infectious diseases. In North America, the high adoption of IHC tests can be attributed to advanced healthcare infrastructure, research capabilities, and a commitment to personalized medicine. With numerous hospitals, research institutes, and clinics In the US and Canada, sophisticated diagnostic tests like IHC are routinely performed. These facilities are at the forefront of medical innovation, collaborating with academic and research organizations to develop new diagnostic techniques and therapeutic strategies. IHC is an essential tool in cancer research, aiding In the identification of specific antigens and antibodies, and contributing to the development of companion diagnostics and immunotherapy trials.

      Digital pathology, IVD equipment, and laboratory consumables are integral components of IHC testing. Companies such as Leica Biosystems, Akoya Biosciences, Roche, and others provide solutions for IHC, digital immunohistochemistry, and multiplex immunohistochemistry. Standardization and automation are critical to ensuring diagnostic accuracy and consistency. IHC is also used In the diagnosis and monitoring of cardiovascular diseases, such as ischemic heart disease and stroke, and In the detection of viral epidemics, including monkeypox. The geriatric population and chronic diseases further drive the demand for IHC testing due to the increased prevalence of these conditions. Reimbursement policies and healthcare professional education are essential factors influencing the market growth.

      In summary, IHC is a vital diagnostic tool In the US and Canadian healthcare systems, driving research, innovation, and precision medicine.

      Market Dynamics

      Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

      What are the key market drivers leading to the rise In the adoption of Immunohistochemistry Industry?

      Increasing number of cancer patients globally is the key driver of the market.

    • The global immunohistochemistry (IHC) market is experiencing significant growth due to the increasing number of cancer patients worldwide. Cancer is the leading cause of death, accounting for approximately 10 million deaths in 2020, or one in every six deaths. The most common types of cancer are breast, lung, colon, rectal, and prostate cancer. Infections such as human papillomavirus (HPV) and hepatitis contribute to approximately 30% of cancer cases in low- and lower-middle-income countries. The rising cancer incidence necessitates increased research and development of new treatments and a better understanding of disease mechanisms. IHC tests play a crucial role in cancer diagnosis and therapeutic decision-making, particularly In the context of companion diagnostics and immunotherapy trials.
    • These tests involve the use of antibodies or antibody fragments to identify specific antigens in tissue samples, providing valuable diagnostic accuracy and therapeutic significance. Digital pathology and automation are transforming the IHC market, with companies such as Leica Biosystems and Akoya Biosciences leading the way in digital IHC and multiplex IHC technologies. IVD equipments and laboratory consumables are essential components of IHC testing, ensuring diagnostic testing standards are met. Chronic diseases, including cardiovascular diseases such as ischemic heart disease and stroke, also benefit from IHC testing. Infectious diseases, including cancer-causing viruses like HPV and monkeypox, are diagnosed using IHC and immunofluorescence assays.
    • Standardization and regulatory compliance are essential considerations In the IHC market. Healthcare professionals rely on IHC tests to make informed decisions, and diagnostic accuracy is paramount. Reimbursement policies and healthcare budgets also impact the market dynamics. As research organizations continue to explore the therapeutic potential of personalized medicine, the role of IHC in identifying biomarkers and predicting treatment responses will become increasingly significant. The IHC market is expected to continue growing, driven by the increasing prevalence of cancer and other chronic diseases, the development of new technologies, and the need for accurate and reliable diagnostic testing.

      • What are the market trends shaping the Immunohistochemistry Industry?

      Automation and technological advancements in immunohistochemistry processes is the upcoming market trend.

    • The Immunohistochemistry (IHC) market is experiencing significant advancements due to the integration of automation and digitalization in cancer disease diagnostics. IHC tests play a crucial role in identifying specific antigens in tissue samples, contributing to diagnostic accuracy and therapeutic significance in cancer and chronic diseases. Automated IHC systems offer standardized incubation times and uniform staining patterns, reducing manual errors and enhancing reproducibility. This is particularly beneficial for diagnostic laboratories handling large volumes of samples. Digital pathology, a key component of this transformation, enables the digitization of IHC slides, allowing for easier data sharing, analysis, and storage. Leading companies such as Leica Biosystems and Akoya Biosciences are at the forefront of this innovation, offering digital IHC solutions.
    • The adoption of digital IHC is further boosted by the development of multiplex immunohistochemistry, which allows for the simultaneous detection of multiple biomarkers, enhancing diagnostic capabilities. IVD equipment manufacturers like Roche are also investing in companion diagnostics, which combine IHC tests with therapeutic interventions, improving patient outcomes in cancer immunotherapy trials. The healthcare professional community, academic and research institutions, and diagnostic testing organizations are embracing these advancements, as they offer significant improvements in diagnostic accuracy and personalized medicine. The market for IHC kits, antibodies, and laboratory consumables continues to grow, driven by the increasing demand for these tools in cancer research, chronic diseases, and infectious diseases.
    • The geriatric population, with its increased susceptibility to various diseases, is another significant market driver. Digital immunohistochemistry and immunofluorescence assay are expected to further expand the market, offering enhanced sensitivity and specificity. Despite these advancements, challenges remain, including reimbursement policies, viral epidemics, and the need for standardization. The market's future growth will depend on addressing these challenges while continuing to innovate and improve the accuracy, efficiency, and affordability of IHC testing.

      • What challenges does the Immunohistochemistry Industry face during its growth?

      High cost associated with immunohistochemistry is a key challenge affecting the industry growth.

    • The global Immunohistochemistry (IHC) market is driven by the increasing prevalence of cancer diseases and chronic conditions, necessitating diagnostic accuracy through IHC tests. Digital pathology and automation are transforming IHC, with companies like Leica Biosystems and Akoya Biosciences leading the way in digital immunohistochemistry. Standardization and companion diagnostics, such as those from Roche, play a crucial role in enhancing diagnostic precision and therapeutic significance in cancer immunotherapy trials. The high cost of immunohistochemistry remains a challenge, with expensive reagents and antibodies, including monoclonal antibodies and antibody fragments, being essential components. Moreover, the investment required for IVD equipments and instruments, such as automated platforms and specialized imaging systems, can be prohibitive for smaller laboratories and research organizations.
    • The healthcare professional community relies on IHC for cancer diagnosis and monitoring, chronic disease management, and infectious diseases research. Digital immunohistochemistry and multiplex IHC offer potential cost savings and improved diagnostic capabilities. However, reimbursement policies and viral epidemics, such as monkeypox, pose challenges to market growth. In the US, cardiovascular diseases, including ischemic heart disease and stroke, account for a significant portion of healthcare spending. IHC plays a vital role In the diagnosis and monitoring of these conditions, making it an essential tool for personalized medicine and improving patient outcomes. Laboratory consumables and diagnostic testing are integral to the IHC market, with a growing focus on antibody drug conjugates and immunofluorescence assays.
    • The academic and research sector continues to contribute significantly to the market's growth, driving innovation and expanding the application of IHC in various fields.

      • Exclusive Customer Landscape

      The immunohistochemistry market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the immunohistochemistry market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

      Immunohistochemistry Market Share by Geography

       Customer Landscape

      Key Companies & Market Insights

      Companies are implementing various strategies, such as strategic alliances, immunohistochemistry market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

      Agilent Technologies Inc. - The company's immunohistochemistry portfolio is a comprehensive solution, prioritizing quality and service to streamline workflows, minimize variation, and reduce potential staining imperfections. This portfolio caters to the diagnostic and research markets, offering a range of validated antibodies and assays for various applications. By focusing on consistency and accuracy, the company aims to provide reliable results, ensuring confidence in research and diagnostic outcomes.

      The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

      • Agilent Technologies Inc.
      • Bio Rad Laboratories Inc.
      • Bio SB
      • Bio Techne Corp.
      • Biocare Medical LLC
      • BioGenex Laboratories Inc.
      • CANDOR Bioscience GmbH
      • Cell Signaling Technology Inc.
      • Danaher Corp.
      • Eagle Biosciences Inc.
      • Elabscience Biotechnology Inc.
      • F. Hoffmann La Roche Ltd.
      • Lunaphore Technologies SA
      • Merck KGaA
      • Miltenyi Biotec B.V. and Co. KG
      • PerkinElmer Inc
      • PHC Holdings Corp.
      • SAKURA SEIKI Co. Ltd.
      • Takara Holdings Inc.
      • Thermo Fisher Scientific Inc.

      Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

      Research Analyst Overview

      Immunohistochemistry (IHC) is a vital technique used In the field of pathology and research to identify specific proteins or antigens in cells and tissues. This method has been instrumental in advancing our understanding of various diseases, including cancer and infectious diseases, and In the development of personalized medicine and therapeutic interventions. The global market for IHC is driven by several factors, including the increasing incidence of chronic diseases such as cancer and cardiovascular diseases. The geriatric population, which is more susceptible to these diseases, also contributes to the growth of the market. The need for accurate and reliable diagnostic tests to aid In the early detection and treatment of diseases is another significant factor.

      Automation and digitalization are key trends In the IHC market. Digital pathology, which involves the digitization of glass slides and the analysis of images using computer algorithms, is gaining popularity due to its efficiency and accuracy. Digital IHC, which combines digital pathology with IHC, offers several advantages, including faster turnaround time, improved reproducibility, and the ability to perform multiplex IHC, which allows for the detection of multiple markers in a single test. The use of IHC in research organizations and academic institutions is also driving market growth. Researchers In the field of immunology and infectious diseases are utilizing IHC to gain insights into disease mechanisms and to develop new therapeutic interventions.

      Companion diagnostics, which are tests that are used in conjunction with therapeutic drugs to identify patients who are most likely to respond to treatment, are also gaining traction In the market. The standardization of IHC protocols and the availability of high-quality antibodies and kits are crucial for the consistent and reliable performance of IHC tests. Laboratory consumables, such as slides and buffers, also play a critical role in ensuring the success of IHC experiments. The use of IHC In the diagnosis of infectious diseases, such as monkeypox and viral epidemics, is another area of growth. IHC is a valuable tool for identifying the presence of specific viral antigens in clinical samples, which can aid In the diagnosis and treatment of these diseases.

      Reimbursement policies and regulatory approvals are important considerations for the market. The availability of reimbursement for IHC tests and the regulatory approval of new IHC-based diagnostic tests can significantly impact market growth. In conclusion, the global market for IHC is driven by the increasing incidence of chronic diseases, the need for accurate and reliable diagnostic tests, and the trends towards automation and digitalization. The use of IHC in research, personalized medicine, and infectious disease diagnosis is also contributing to market growth. Standardization, the availability of high-quality antibodies and kits, and regulatory approvals are crucial factors for the success of the market.

      Market Scope

      Report Coverage

      Details

      Page number

      168

      Base year

      2023

      Historic period

      		 2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 8.36%

      Market growth 2024-2028

      USD 1.33 billion

      Market structure

      Fragmented

      YoY growth 2023-2024(%)

      7.63

      Key countries

      US, Germany, France, UK, and China

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Request Free Sample

      What are the Key Data Covered in this Immunohistochemistry Market Research and Growth Report?

      • CAGR of the Immunohistochemistry industry during the forecast period
      • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
      • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
      • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
      • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
      • Thorough analysis of the market’s competitive landscape and detailed information about companies
      • Comprehensive analysis of factors that will challenge the immunohistochemistry market growth of industry companies

      We can help! Our analysts can customize this immunohistochemistry market research report to meet your requirements.

      Get in touch

       

      Table of Contents not available.

      Research Methodology

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      INFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases

      DATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts

      REPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape

      Interested in this report?

      Get your sample now to see our research methodology and insights!

      Download Now

      Frequently Asked Questions

      Immunohistochemistry market growth will increase by $ 1.33 bn during 2024-2028.

      The Immunohistochemistry market is expected to grow at a CAGR of 8.36% during 2024-2028.

      Immunohistochemistry market is segmented by Application( Diagnostic application, Research application, Forensic application) End-user( Hospitals and diagnostic laboratories, Academic and research institutes, Others)

      Agilent Technologies Inc., Bio Rad Laboratories Inc., Bio SB, Bio Techne Corp., Biocare Medical LLC, BioGenex Laboratories Inc., CANDOR Bioscience GmbH, Cell Signaling Technology Inc., Danaher Corp., Eagle Biosciences Inc., Elabscience Biotechnology Inc., F. Hoffmann La Roche Ltd., Lunaphore Technologies SA, Merck KGaA, Miltenyi Biotec B.V. and Co. KG, PerkinElmer Inc, PHC Holdings Corp., SAKURA SEIKI Co. Ltd., Takara Holdings Inc., Thermo Fisher Scientific Inc. are a few of the key vendors in the Immunohistochemistry market.

      North America will register the highest growth rate of 38% among the other regions. Therefore, the Immunohistochemistry market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

      US, Germany, France, UK, China

      • Increasing number of cancer patients globallyThe increasing number of cancer patients globally is a significant healthcare challenge that has far-reaching implications for healthcare systems is the driving factor this market.
      • research is the driving factor this market.
      • and public health initiatives. Cancer is the leading cause of death worldwide is the driving factor this market.
      • accounting for nearly 10 million deaths in 2020 is the driving factor this market.
      • or roughly one in every six deaths. The most common cancers are breast is the driving factor this market.
      • lung is the driving factor this market.
      • colon is the driving factor this market.
      • rectal is the driving factor this market.
      • and prostate cancer. Cancer-causing infections such as human papillomavirus (HPV) and hepatitis is the driving factor this market.
      • account for roughly 30% of cancer cases in low- and lower-middle-income countries. The rising cancer incidence drives increased research efforts to develop new treatments and understand disease mechanisms. The growing number of cancer patients worldwide is a major driver of the global immunohistochemistry market. Immunohistochemistry is important in cancer diagnosis and research because it allows for the identification and characterization of specific proteins in tissue samples. As the incidence of cancer rises is the driving factor this market.
      • so does the demand for accurate and reliable diagnostic tools is the driving factor this market.
      • making immunohistochemistry an essential technology for the detection is the driving factor this market.
      • classification is the driving factor this market.
      • and prognosis of various cancer types. Vendors of immunohistochemistry solutions contribute to this growth by offering a wide range of antibodies is the driving factor this market.
      • detection systems is the driving factor this market.
      • and automated platforms designed specifically for cancer research and pathology. For example is the driving factor this market.
      • F. Hoffmann La Roche Ltd. is the driving factor this market.
      • a major player in the immunohistochemistry market is the driving factor this market.
      • provides a comprehensive portfolio of cancer diagnostic reagents and instruments. Similarly is the driving factor this market.
      • companies such as Agilent Technologies Inc. and Thermo Fisher Scientific Inc. offer advanced immunohistochemistry technologies that help with the precise identification of cancer biomarkers. Immunohistochemistry versatility in assessing protein expression and localization within tumour tissues increases its usefulness in personalized medicine and targeted therapies. Researchers and clinicians can use immunohistochemistry to identify specific molecular targets for drug development is the driving factor this market.
      • resulting in more effective and personalized treatment plans for cancer patients. The increasing number of global cancer patients is driving the demand for accurate and efficient diagnostic techniques such as immunohistochemistry is the driving factor this market.
      • particularly in cancer diagnostics is the driving factor this market.
      • prognosis is the driving factor this market.
      • and therapeutic decision-making is the driving factor this market.
      • which will propel the growth of the global immunohistochemistry market during the forecast period. is the driving factor this market.

      The Immunohistochemistry market vendors should focus on grabbing business opportunities from the Diagnostic application segment as it accounted for the largest market share in the base year.